Info@ThinkPinkRocks.com

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Salix Pharmaceuticals and Pharming Group NV announced today that the U.S. Food and Drug Administration has granted 12 years of exclusivity to RUCONEST (C1 esterase inhibitor [recombinant]) 50 IU/kg.

View article:
FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Share

Leave a Reply